MBHB Partner Kevin Noonan Featured in Practical Law IP & Technology Article Entitled, “Expert Q&A on Biosimilar Patent Litigation under the BPCIA”

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is featured in a November 2014 edition of the Practical Law Intellectual Property & Technology in an article entitled, “Expert Q&A on Biosimilar Patent Litigation under the BPCIA.” After many years of patent litigation on small molecule drugs under the Hatch-Waxman Act, drug companies and their counsel are now starting to explore patent litigation on biosimilars under the Biologics Price Competition and Innovation Act of 2009 (BPCIA). Practical Law asked Dr. Noonan of to explain the key features of the BPCIA, the requirements and implications of patent litigation under the BPCIA and how it differs from the Hatch-Waxman Act. View the article